Xbrane Biopharma informs that trading in subscription rights and interim shares is delayed and will be initiated 12 March 2019

English IR Press Release Regulatory

Press release
11 March 2019

The Board of Directors in Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has today been informed that the Companys subscription rights and interim shares (Ticker: XBRANE TR, ISIN: SE0012376994 and ticker: XBRANE BTA ISIN: SE0012377000) have not been registered. The error in registering the subscription rights in the system has been resolved and trading will commence 12 March 2019.

Xbrane has today been informed that the Companys subscription rights (Ticker: XBRANE TR, ISIN: SE0012376994 and ticker: XBRANE BTA ISIN: SE0012377000) have not been registered in Nasdaq First North Listing Center and that the trading in the Companys subscription rights that was planned to start on 11 March 2019, thus being delayed. The error in registering the subscription rights in Nasdaq First North Listing Center has been resolved and trading will be initiated 12 March 2019.

For more information, contact:

Martin Åmark, CEO/IR
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

Susanna Helgesen, CFO
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com

About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified adviser (corp@avanza.se, +46 (0)8 409 421 20). For more information seewww.xbrane.com.

Trading in subscription rights and interim shares is delayed


This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Xbrane Biopharma AB via Globenewswire